> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Redeemed for Alexion’s Ultomiris
- URL: https://www.fdaweb.com/priority-voucher-redeemed-for-alexions-ultomiris/
- Published: 2022-06-28T12:00:00.000Z
- Updated: 2026-09-14T17:50:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152184

*Federal Register* notice: FDA has announced the approval of a product that redeemed a priority review voucher — AstraZenca’s sBLA for Ultomiris (ravulizumab-cwvz) that was approved 4/27 for treating adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-06-27/pdf/2022-13628.pdf?ref=fdaweb.com).